14 results about "CDK4 Inhibitor" patented technology

The present application provides compounds of Formula (I):or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Various salt forms and free bases of compound (I) represented by the following chemical formula are disclosed (I).

Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

Disclosed herein are compounds used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

Disclosed are various salt forms and the free base of Compound (I) represented by the following formula. (I).

This invention relates to, in part, a method for treating cancer by administering a CDK4 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an CDK2 inhibitor to a subject in need thereof.

strutural formula: F N N N N N N N N N cancer. 20 26 20 09 99 11 F eb 2 02 6 A B S T R A C T 2 0 2 6 2 0 0 9 9 9 1 1 F e b 2 0 2 6 F N N N N N N N N c a n c e r . A B S T R A C T 2 0 2 6 2 0 0 9 9 9 1 1 F e b 2 0 2 6 F N N N N N N N N c a n c e r .

Provided are a pharmaceutical combination and a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form thereof and at least one other anticancer agent, and use thereof in the preparation of a medicine for treating a malignant tumor disease. The other anticancer agent is a CDK inhibitor or a pharmaceutically acceptable salt thereof (such as palbociclib), lenvatinib or a pharmaceutically acceptable salt thereof, sorafenib or a pharmaceutically acceptable salt thereof, or any combination of the above.

The present invention relates to a CDK kinase inhibitor and its pharmaceutical use. In particular, the present invention relates to a CDK inhibitor having the structure of formula (I) and its pharmaceutical composition, and its use as a CDK inhibitor and its use in the manufacture of a medicament for treating a cancer or a tumor at least partially associated with CDK. Wherein each substituent of formula (I) is the same as defined in the specification.

The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

The application discloses a CDK4 / PARP1 dual-target inhibitor and application, belongs to the medical technology field, solves the problems of poor effect of a single CDK4 inhibitor and weak activity of a single PARP1 inhibitor, the inhibitor is a compound with structural general formula A-Linker-B, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, the dual-target inhibitor disclosed in the application can effectively overcome the defects of poor effect of a single CDK4 inhibitor and weak activity of a single PARP1 inhibitor, and has a strong inhibitory effect on CDK4 and PARP1, and has a good application prospect.